Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials
Marla C. Dubinsky, Stefan Schreiber, Stephen B. Hanauer, Silvio Danese, Andres J. Yarur, Bruce E. Sands, Hyunseong Yu, Dong-Hyeon Kim, Young Nam Lee, Jean-Frédéric Colombel
Topic of the month
Julho 2026
Artificial Intelligence in Inflammatory Bowel Disease